Seth Porter

1.0k total citations
21 papers, 799 citations indexed

About

Seth Porter is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Seth Porter has authored 21 papers receiving a total of 799 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Pulmonary and Respiratory Medicine, 10 papers in Molecular Biology and 7 papers in Oncology. Recurrent topics in Seth Porter's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Connective Tissue Growth Factor Research (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Seth Porter is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (8 papers), Connective Tissue Growth Factor Research (7 papers) and Pancreatic and Hepatic Oncology Research (6 papers). Seth Porter collaborates with scholars based in United States, Italy and Germany. Seth Porter's co-authors include Jonathan Goldin, Thomas B. Neff, Ganesh Raghu, Kevin R. Flaherty, Mary Beth Scholand, Stanley C. Froehner, Elias Kouchakji, Ming Zhong, Ulrich Costabel and Luca Richeldi and has published in prestigious journals such as Journal of Clinical Oncology, Biochemistry and British Journal of Pharmacology.

In The Last Decade

Seth Porter

21 papers receiving 771 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Seth Porter United States	11	287	235	129	125	108	21	799
Fumiya Hongo Japan	17	342 1.2×	435 1.9×	96 0.7×	217 1.7×	58 0.5×	108	973
Nektaria Makrilia Greece	15	287 1.0×	280 1.2×	82 0.6×	325 2.6×	59 0.5×	23	1.0k
Angelina Di Carlo Italy	19	200 0.7×	303 1.3×	69 0.5×	157 1.3×	36 0.3×	37	777
Lisa Seitz United States	12	253 0.9×	157 0.7×	356 2.8×	135 1.1×	65 0.6×	35	780
Qingfang Li China	17	222 0.8×	437 1.9×	175 1.4×	336 2.7×	30 0.3×	37	1.0k
Shinji Kikuchi Japan	13	178 0.6×	295 1.3×	63 0.5×	178 1.4×	97 0.9×	56	791
E. K. J. Pauwels Netherlands	13	180 0.6×	239 1.0×	88 0.7×	104 0.8×	54 0.5×	40	673
Jędrzej Grzegrzółka Poland	18	169 0.6×	466 2.0×	140 1.1×	427 3.4×	100 0.9×	76	1.1k
Faruk Taş Türkiye	15	99 0.3×	154 0.7×	95 0.7×	235 1.9×	42 0.4×	44	585

Countries citing papers authored by Seth Porter

Since Specialization

Citations

This map shows the geographic impact of Seth Porter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Seth Porter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Seth Porter more than expected).

Fields of papers citing papers by Seth Porter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Seth Porter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Seth Porter. The network helps show where Seth Porter may publish in the future.

Co-authorship network of co-authors of Seth Porter

This figure shows the co-authorship network connecting the top 25 collaborators of Seth Porter. A scholar is included among the top collaborators of Seth Porter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Seth Porter. Seth Porter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Picozzi, Vincent J., Adnan Alseidi, Michael J. Pishvaian, et al.. (2020). Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 5(4). e000668–e000668. 54 indexed citations

Richeldi, Luca, Evans R. Fernández Pérez, Ulrich Costabel, et al.. (2019). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. The Lancet Respiratory Medicine. 8(1). 25–33. 215 indexed citations

Richeldi, Luca, Evans R. Fernández Pérez, Ulrich Costabel, et al.. (2019). Pamrevlumab (FG-3019), an Anti-Connective Tissue Growth Factor Therapy for Idiopathic Pulmonary Fibrosis: A Randomized, Double-Blind, Placebo-Controlled Trial. SSRN Electronic Journal. 1 indexed citations

Picozzi, Vincent J., Flavio G. Rocha, Michael J. Pishvaian, et al.. (2019). Gemcitabine/Nab-Paclitaxel and Pamrevlumab in Locally Advanced Pancreatic Cancer (LAPC): A Phase 1/2 Trial. SSRN Electronic Journal. 1 indexed citations

Picozzi, Vincent J., Flavio G. Rocha, Scott Helton, et al.. (2017). Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. Journal of Clinical Oncology. 35(4_suppl). 365–365. 8 indexed citations

Goldin, Jonathan, et al.. (2017). Short term Quantitative Lung Fibrosis (QLF) change predicts rapid rate of FVC decline in patients with IPF. PA853–PA853. 1 indexed citations

Goldin, Jonathan, et al.. (2017). Automatic quantitative fibrosis scores at baseline is a predictor of progression in patients with IPF. OA1957–OA1957. 1 indexed citations

Gorina, Eduard, Luca Richeldi, Ganesh Raghu, et al.. (2017). PRAISE, a randomized, placebo-controlled, double-blind Phase 2 clinical trial of pamrevlumab (FG-3019) in IPF patients. OA3400–OA3400. 18 indexed citations

Porter, Seth, Elias Kouchakji, Eduard Gorina, et al.. (2017). Late Breaking Abstract - Assessment of disease progression in IPF patients using Functional Respiratory Imaging (FRI). OA1952–OA1952. 1 indexed citations

10.

Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2016). FG-3019, A Human Monoclonal Antibody to Connective Tissue Growth Factor, Combined with Chemotherapy in Patients with Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma. 2(1). 1–8. 8 indexed citations

11.

Picozzi, Vincent J., Flavio G. Rocha, Scott Helton, et al.. (2016). Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).. Journal of Clinical Oncology. 34(4_suppl). 457–457. 2 indexed citations

12.

Raghu, Ganesh, Mary Beth Scholand, João A. de Andrade, et al.. (2016). FG-3019 anti-connective tissue growth factor monoclonal antibody: results of an open-label clinical trial in idiopathic pulmonary fibrosis. European Respiratory Journal. 47(5). 1481–1491. 140 indexed citations

13.

Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2014). FG-3019, a human monoclonal antibody to connective tissue growth factor (CTGF), with gemcitabine/erlotinib (G/E) in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 32(15_suppl). 4138–4138. 10 indexed citations

14.

Picozzi, Vincent J., J. Marc Pipas, Albert C. Koong, et al.. (2013). FG-3019, a human monoclonal antibody to CTGF, with gemcitabine/erlotinib in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.. Journal of Clinical Oncology. 31(4_suppl). 213–213. 6 indexed citations

15.

Raghu, Ganesh, Mary Beth Scholand, João A. de Andrade, et al.. (2012). Phase 2 trial of FG-3019, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results. 40. 2819. 5 indexed citations

16.

Pineda, Alvaro A., Jeffrey McCullough, Richard J. Benjamin, et al.. (2006). Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion. 46(4). 562–571. 22 indexed citations

17.

Lin, Lily, Maureen G. Conlan, John W. Tessman, George D. Cimino, & Seth Porter. (2005). Amotosalen interactions with platelet and plasma components: absence of neoantigen formation after photochemical treatment. Transfusion. 45(10). 1610–1620. 40 indexed citations

18.

Porter, Seth. (2001). Human Immune Response to Recombinant Human Proteins. Journal of Pharmaceutical Sciences. 90(1). 1–11. 129 indexed citations

19.

Stanley, William C., Bin Li, Douglas W. Bonhaus, et al.. (1997). Catecholamine modulatory effects of nepicastat (RS‐25560‐197), a novel, potent and selective inhibitor of dopamine‐β‐hydroxylase. British Journal of Pharmacology. 121(8). 1803–1809. 78 indexed citations

20.

Porter, Seth & Stanley C. Froehner. (1985). Interaction of the 43K protein with components of Torpedo postsynaptic membranes. Biochemistry. 24(2). 425–432. 44 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact